Industry News
Biotechnology Industry News
Improving CAR-T cell therapies for cancer by targeting a protein ‘brake’
Improving CAR-T cell therapies for cancer by targeting a protein 'brake' aliu Wed, 12/01/2021 - 07:28
Apollo’s mission to extend human health span gets $180M boost, giving VC fund a launchpad for age-related disease biotechs
Apollo's mission to extend human health span gets $180M boost, giving VC fund a launchpad for age-related disease biotechs ntaylor Wed, 12/01/2021 - 04:50
Britain led the way in COVID trials, but overall clinical study activity still lags: report
Britain led the way in COVID trials, but overall clinical study activity still lags: report badams Wed, 12/01/2021 - 04:44
Sanofi snaps up Origimm for early-phase acne vaccine, opening new front in mRNA strategy
Sanofi snaps up Origimm for early-phase acne vaccine, opening new front in mRNA strategy ntaylor Wed, 12/01/2021 - 02:16
Mei, with Bayer and Gilead in its sights, posts pivotal data on blood cancer prospect
Mei, with Bayer and Gilead in its sights, posts pivotal data on blood cancer prospect ntaylor Tue, 11/30/2021 - 08:54
GlaxoSmithKline poaches Pfizer vax leader Dormitzer after hemorrhaging vaccine R&D talent
GlaxoSmithKline poaches Pfizer vax leader Dormitzer after hemorrhaging vaccine R&D talent badams Tue, 11/30/2021 - 08:47
ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial
ImmunoGen lines up FDA filing as antibody-drug conjugate shrinks tumors in pivotal trial ntaylor Tue, 11/30/2021 - 07:52
Chinook launches a new biotech with major VCs in China to double down on kidney disease R&D
Chinook launches a new biotech with major VCs in China to double down on kidney disease R&D badams Tue, 11/30/2021 - 03:45
RAGE against diabetes complications: Novel drug tamps down tissue damage in mice
RAGE against diabetes complications: Novel drug tamps down tissue damage in mice arlene.weintraub Mon, 11/29/2021 - 12:45
Could common antihistamines be the key to boosting immuno-oncology treatments?
Could common antihistamines be the key to boosting immuno-oncology treatments? arlene.weintraub Mon, 11/29/2021 - 09:23
Turnstone teams up with Moffitt to race TIL cell therapies into the clinic
Turnstone teams up with Moffitt to race TIL cell therapies into the clinic ntaylor Mon, 11/29/2021 - 08:08
Is molnupiravir a turkey? Merck slips out drop in efficacy of COVID-19 antiviral over Thanksgiving period
Is molnupiravir a turkey? Merck slips out drop in efficacy of COVID-19 antiviral over Thanksgiving period ntaylor Mon, 11/29/2021 - 06:19
Next-gen CAR player Quell Therapeutics drives into the fast lane with major $156M round
Next-gen CAR player Quell Therapeutics drives into the fast lane with major $156M round badams Mon, 11/29/2021 - 04:49
FDA halts phase 1b Kura Oncology trial in acute myeloid leukemia following patient death
FDA halts phase 1b Kura Oncology trial in acute myeloid leukemia following patient death klahucik Wed, 11/24/2021 - 08:47
Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet
Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet ntaylor Wed, 11/24/2021 - 08:23
Kymera’s first-in-class protein degrader shows potential to boost cancer immunotherapy
Kymera's first-in-class protein degrader shows potential to boost cancer immunotherapy aliu Wed, 11/24/2021 - 07:10
Acorda CMO hits the exit, landing Pharnext job with oversight of phase 3 neurological disorder trial
Acorda CMO hits the exit, landing Pharnext job with oversight of phase 3 neurological disorder trial ntaylor Wed, 11/24/2021 - 05:52
Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO
Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO ntaylor Tue, 11/23/2021 - 08:03
AstraZeneca, after years of delays and spiraling costs, opens Cambridge R&D site. Will the bet pay off?
AstraZeneca, after years of delays and spiraling costs, opens Cambridge R&D site. Will the bet pay off? ntaylor Tue, 11/23/2021 - 05:06
Vaccibody, now Nykode, celebrates new name with a Regeneron deal worth $900M-plus
Vaccibody, now Nykode, celebrates new name with a Regeneron deal worth $900M-plus badams Tue, 11/23/2021 - 03:28